Reports Q1 revenue $132M, consensus $122.51M. “With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis’ new chapter as a fully integrated, commercial-stage biotechnology company is well underway,” said Brett Monia, chief executive officer, Ionis. “We look forward to continued momentum this year, including our second independent launch for donidalorsen in hereditary angioedema and Phase 3 results for olezarsen for severe hypertriglyceridemia in the third quarter. We also continue to advance our next wave of wholly owned neurology medicines, including ION582 for Angelman syndrome, which is on track to start Phase 3 development shortly. Our advancing pipeline of transformational medicines, together with strong commercial and financial execution, position Ionis to deliver increasing value for all stakeholders.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- IONS Earnings this Week: How Will it Perform?
- Ionis Pharmaceuticals’ Tryngolza: Promising Treatment for Severe Hypertriglyceridemia with Strong Market Potential
- Buy Rating for Ionis Pharmaceuticals: Promising Potential of Olzesarsen in sHTG Treatment
- Promising Potential of Ionis Pharmaceuticals’ Olezarsen in sHTG Market with Competitive Pricing and Strong Market Potential
- Ionis Pharmaceuticals: Promising Market Growth with Tryngolza Approval and Advancing Clinical Trials
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue